Assembly Biosciences (ASMB) Enterprise Value (2010 - 2026)

Assembly Biosciences' Enterprise Value history runs 17 years deep, the most recent figure standing at -$226.6 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 148.94% year-over-year to -$226.6 million in Q1 2026; TTM through Mar 2026 was -$226.6 million, a 148.94% decrease from a year earlier, with the FY2025 full-year figure at -$248.1 million, down 121.37% from the prior year.
• Enterprise Value climbed to -$226.6 million in Q1 2026 per ASMB's latest filing, from -$248.1 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$46.2 million in Q3 2023 and bottomed at -$248.1 million in Q4 2025.
• The 5-year median for Enterprise Value is -$109.2 million (2024), against an average of -$120.7 million.
• Across the five-year window, Enterprise Value jumped 57.47% in 2023 and plunged 148.94% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$91.6 million in 2022, then tumbled by 42.18% to -$130.2 million in 2023, then grew by 13.95% to -$112.1 million in 2024, then slumped by 121.37% to -$248.1 million in 2025, then grew by 8.67% to -$226.6 million in 2026.
• Per Business Quant, the three latest ASMB Enterprise Value figures stand at -$226.6 million (Q1 2026), -$248.1 million (Q4 2025), and -$232.6 million (Q3 2025).